New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Metagenics' Research on the Safety and Efficacy of Hops-derived Anti-inflammatory Compounds Published in Peer-Reviewed, Scientific Journal

SAN CLEMENTE, Calif. (July 1, 2008)—Metagenics, Inc., a leading developer and manufacturer of science-based medical foods and nutraceuticals sold through healthcare practitioners, today announced the publication of a scientific paper, “Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops,” in the May issue of Phytochemistry, the International Journal of Plant Chemistry, Plant Biochemistry and Molecular Biology.

In an aging population, millions are seeking relief from minor pain and joint discomfort. Non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 inhibitors, are among the most widely prescribed medications in the world. However, NSAIDs have been known to produce adverse reactions in some people. Previous work by the Metagenics MetaProteomics® nutrigenomics research center had identified a defined mixture of rho iso-alpha-acids (RIAA), a derivative of hops (Humulus lupulus L.), as a potent and selective COX-2 inhibitor. The Phytochemistry paper summarizes the results of several new studies conducted by Metagenics evaluating the efficacy and safety of RIAA. Among the findings:

· Clinically, the RIAA mixture produced a 54% reduction in WOMAC Global scores (a standard measurement used to assess the symptoms of pain, stiffness and physical function), in patients exhibiting knee osteoarthritis.

· RIAA was shown to selectively inhibit the inducible (inflammatory) activity of COX-2 without affecting constitutive (housekeeping) COX-2 activity.

· Compared to conventional methods, the RIAA mixture was shown to have a lower potential for gastrointestinal and cardiovascular adverse reactions.

According to Jeffrey S. Bland, PhD, Metagenics Chief Science Officer and President of MetaProteomics, “Based on our cumulative research, RIAA appears to have the potential to serve as a safe and efficacious option in some areas where specific COX-2 inhibitors have been traditionally used. We’re excited about the possibilities in helping millions of people who are looking for safer approaches for pain relief.”

About Metagenics, Inc.

Metagenics is a life sciences company and leading developer and manufacturer of professional grade, science-based medical foods and nutraceuticals sold to healthcare practitioners worldwide. For more than 25 years, Metagenics has been a leader in quality, scientific discovery, and innovation, with multiple proprietary formula patents and more than 400 research-based products to optimize health. The company is headquartered in San Clemente, CA, with manufacturing and research facilities located in Gig Harbor, WA, including the MetaProteomics® Nutrigenomics Research Center and the Functional Medicine Research CenterSM for human clinical research. For more information, please visit


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.